I think they could sell PBT2 to be used in cases of treatment-resistant infections and perhaps PBT434 to be used as eye drops (macular degeneration). Few millions of cash and then royalties every quarter. Or something else must be cooking. This Life bio news last week was known to the management for a long time because Sinclair et al are sitting on the board. We investors are sitting in the dark but there are solutions.
The plan after the phase I results with PBT434 was to start phase II during the first 6 months of 2020. It sounds slow IMO but here we are.
What are they doing?, page-4
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.96M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 38 | 22150822 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 130766828 | 31 |
View Market Depth
| Last trade - 12.49pm 09/10/2024 (20 minute delay) ? |
| ATH (ASX) Chart |
Day chart unavailable